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ABSTRACT
The prevalence of Escherichia coli O157:H7 induced bacteremia generate a critical problem in
modern medical therapy for bacterial infections. This study sought to find out the best possible
route and dose of E. coli 0157:H7 infection in experimental murine model by periodic stool and
blood culture count of relevant bacterial strains.  Streptomycin treated mouse model were used for
investigating the clinical manifestation exerted by stx1A and stx2A positive E. coli O157:H7 with
increasing doses applied through three alternative routes (oral, intramuscular and intraperitoneal).
The highest titer of orally added E. coli 0157:H7 among five test doses started showing symptoms
at the earliest time and reached moribund condition about 48 hours just before being dead. The oral
way of E.coli O157:H7 at the dose of 100 l suspension containing 1  109CFU ml-1 was taken as
the most potent concentration in producing bacterial fatality and hence was selected as the
minimum lethal dose (MLD).
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INTRODUCTION
Escherichia coli O157:H7 is an enter hemorrhagic strain of the bacterium E. coli
which causes food borne illness. Infection often leads to hemorrhagic diarrhoea, and
occasionally to kidney failure, especially in young children. Enter hemorrhagic
Escherichia coli (EHEC) is an important group of multiple food and water-borne
pathogens. EHEC, including E. coli O157:H7 comprise a subset of Shiga toxin-producing
E. coli (STEC). E. coli O157:H7 has become a worldwide threat to public health and is
one of today’s most troubling food-borne pathogens. E. coli 0157:H7 has been known to
be a human pathogen for nearly 30 years (Nataro et al. 1998).
The centre for disease control (CDC) estimated that about 85% of E. coli O157:H7
infections are food borne in origin. In fact, consumption of any food or beverage that
becomes contaminated by animal (especially cattle) manure can result in contracting the
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disease.  Foods that have been sources of contamination include ground beef, venison,
sausages, dried (non-cooked) salami, unpasteurized milk and cheese, unpasteurized apple
juice and cider (Khan et al. 2003).  The CDC recently reported E. coli O157:H7 as the
fourth most prevalent bacterial diarrhoeal pathogen after Campylobacter sp., Salmonella
sp. and Shigella sp. (Bell et al. 1994).
The pathogenicity of E. coli 0157:H7 is associated with several virulence factors
including shiga toxins or verotoxins 1 and 2 encoded by stx1A and stx2A genes,
respectively. This potent cytotoxin is the major factor that might lead to many symptoms
or even to death in patients infected with EHEC.
There are no currently available vaccines to prevent diseases due to EHEC, but a
number of experimental approaches are being investigated in animals. Numerous in vitro
assays and animal models have been developed in an effort to imitate various aspects of
E. coli O157:H7 mediated disease production in humans. These models exist in two
varieties: those solely focused on the effects of Stx (in the absence of bacteria) and those
that explore E. coli O157:H7 infection. Small animals that have served as models for
EHEC infection and disease include mice, rats and rabbits. Larger animals that have been
so used for experimentation, even though less frequently, include chickens, pigs, cows,
dogs, baboons and macaques (Bell et al. 1994).
This work investigated the clinical manifestation exerted by stx1A and stx2A positive
E. coli O157:H7 in various doses applied through three alternative routes (oral,
intramuscular and intraperitoneal) into healthy conventional rodents over a period to
evaluate the level of E. coli O157:H7 in feces and blood of infected mice at various time
period and compared it to their health status. The objective of the study was to identify
the best possible route of E.coli infection in experimental rodent model by statistical
analysis, hence determining the minimal lethal dose (MLD) of infection.
MATERIALS AND METHODS
E. coli O157:H7 (clinical strain) obtained from ICDDR,B (International Center for
Diarrheal Disease Research) was used.
Bacterial chromosomal DNA was extracted and purified according to GuSCN DNA
extraction method (Khan et al. 2003) to detect the presence of stx1A and stx 2A.
Polymerase chain reactionbased detection of stx1A and stx2A gene from extracted DNA
of bacteria was performed by following the method of Brown (2006).  PCR was
performed in a thermal cycler with program required for each system.
Forty Swiss albino mice (Mus musculus) of 6 - 8 weeks age were randomly selected
on the basis of experimental scheme and to verify the reproducibility of the outcome each
set of investigation was performed in duplication.
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To demonstrate the infective capacity of E. coli O157:H7 in murine model, three sets
of mice (set-1, set-2, and set-3) each containing six animals were administrated with
increasing  dose of E. coli O157:H7 culture (Table 1) through three different routes of
entry: oral, intramuscular and intraperitoneal. Over the course of infection the animals
were observed daily for their activity level, water intake and amount of food consumption
(March et al. 2004). All of the three groups of mice (set 1, 2 and 3) were streptomycin
treated and starved from feed and water for 24 hours.
Treated mice of all the three sets (set 1, 2 and 3) challenged with different dose of E.
coli 0157:H7 (Table 1) along with the untreated (the mice fed with 1% sucrose solution
i.e. negative control) ones were kept under thorough watch for the further 144 hours to
detect any visible change.
The health status of the mice along with the increasing dose of E.coli O157:H7 was
recorded. The dose responsible for the death or maximum worst situation (moribund or
terminally ill) of murine model was determined to establish the MLD.
To verify if the cause of death due to E. coli O157:H7 bacteremia, blood samples
were collected from infected mice by cardiac puncture and then directly spread on CT-
SMAC plate. Freshly voided fecal samples were collected over time along with the
progression of disease symptoms and also spread on CT-SMAC plate (Merril et al.
1996).
Presumptive isolation of E. coli 0157:H7 in both fecal and blood sample was done by
direct plating of serially diluted fecal and blood sample onto CT-SMAC and incubating
for 18 - 24 hours at 37C. From CT-SMAC plates, suspected colorless E. coli O157:H7
isolates were confirmed by cultural properties on EMB and MUG media and by standard
biochemical tests.
RESULTS AND DISCUSSION
The PCR result revealed that clinical strain of E. coli O157:H7 used in this research
was positive for stx1A and stx2A identical to the Shigella dysenteriae stx positive strains
(Khan et al. 2003).
The six mice in each group (An/Bn) were labeled through 1 to 6 (i.e. A1/B1 up to
A6/B6). The mice received various doses of E. coli 0157:H7 according to the list (Table
1) and examined for the symptoms developed for further 144 hours. It is to be noted that
the mice were treated with streptomycin antibiotic to reduce the normal facultative
resident flora of intestine which would have interfered with the clinical picture.
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Table 1. Various titers of orally administered E. coli 0157:H7.
Animal
model
Mouse identification
number (ID No.) in each set
Dose (CFUml-1)
scheme
A1/B1 Dose 1 Negative control (1%
aqueous sucrose solution)
A2/B2 Dose 2 1  105
A3/B3 Dose 3 1  106
A4/B4 Dose 4 1  107
A5/B5 Dose 5 1  108
Mice set-1
A6/B6 Dose 6 1  109
Mice challenged with 105 and 106 CFU ml-1 of E. coli 0157:H7 developed no visible
symptoms while examined for 144 hours since infection, whereas dose 4 (107 CFU ml-1)
and dose 5 (108 CFU ml-1) produced specific symptoms (slight illness like lethargy and
ruffeled fur) at specific times but eventually the experimental animals recovered from
illness. A significant increase of both stool and blood count was observed which was
related to health status. The highest titer of orally added E. coli 0157:H7 (109 CFU ml-1)
showed severe symptoms  like ruffled fur, and hunched back, exudative accumulation
around partially closed eyes tends to moribund state (Lemuel et al. 2004). These
symptoms started to manifest at 14th hour, increased with time and had reached
moribund condition near at 48 hour with an increasing stool and blood count of E. coli
O157:H7 just before being dead. The level of E. coli O157:H7 found in the feces and
blood (Fig. 1) samples collected from infected mice from time to time was found to be
proportionately correlated to their health status.
 Fig. 1. Kinetics of infection monitored by fecal and blood counts for orally
administrated E. coli 0157:H7 at different doses.
To determine the survival pattern of Swiss albino mice of set-2 and 3 (group An/Bn),
increasing dose of E. coli 0157:H7 were injected through intramuscular and
intraperitoneal route following Table 1. For both routes 105 and 106 CFU ml-1 of E. coli
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0157:H7 developed no remarkable symptoms while examined for 144 hours since
infection, but in case of dose 4 (107 CFU ml-1) intramuscularly infected mice gave no
visible symptoms whereas intraperitoneally infected mice produced minor symptoms. For
dose 5 (108 CFU ml-1) and dose 6 (109 CFU ml-1) mice produced minor symptoms like
lethargy at different point of time which was similar for both the routes. Both fecal and
blood count of E. coli 0157:H7 increased for these routes (Figs 2 and 3) but significant
decrease of bacterial counts was observed following next 36 hours of infection.
Fig. 2. The kinetics of infection monitored by fecal and blood counts for
intramuscularly administrated E. coli 0157:H7 at different dose.
The disease severity of mice was found to be correlated with the augmented dose of E.
coli O157:H7. All the three routes of bacterial inoculation shared this observation. However,
the oral way of E. coli O157:H7 addition at a dose of 1  109CFU ml-1 was proved to the most
potent in developing bacterial pathogenesis and hence selected as the MLD.
Fig. 3. Kinetics of infection monitored by fecal and blood counts for intraperitoneally
administered E. coli 0157:H7 at different doses.
The experiment was not prolonged after 6 days to avoid the likelihood of
contamination with other prevailing microorganisms, which would have interfered with
the clinical picture. To verify if the cause of death was truly due to E. coli bacteremia,
blood and stool samples were streaked on CT-SMAC agar and compared to the original
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inoculum, clinical isolate of E. coli O157:H7. The untreated mice group developed no
symptoms and acquired adequate body weight within the studied time frame.
As a result of the increased rate of HC and HUS over the last several years and the
lack of therapies for treatment of HUS, further research is necessary to deﬁne
mechanisms involved in the pathogenesis of E. coli O157:H7 and to identify potential
disease prevention strategies and therapeutics. The application of animal model systems
is vital to achieve these goals. Despite the fact that no one animal model recapitulates all
features of E. coli O157:H7 infection, mouse models have been explored in this research
for understanding E. coli O157:H7 pathogenesis better and by doing so helping to
pinpoint the means by which E. coli O157:H7 infection and/or disease can be controlled
or prevented.
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